J. von Pawel | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where J. von Pawel is active.

Explore More

Publication

Featured researches published by J. von Pawel.

Lung Cancer | 2005

Randomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancer

Eng-Huat Tan; Aleksandra Szczesna; Maciej Krzakowski; H.N. Macha; U. Gatzemeier; Karin Mattson; M. Wernli; P. Reiterer; J. von Pawel; O. Bertetto; J.C. Pouget; J.P. Burillon; Y. Parlier; Raymond P. Abratt

Lung Cancer | 1997

126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study

Alain Depierre; J. von Pawel; K. Hans; D. Moro; Peter I. Clark; U. Gatzemeier; N. Paillot; W. Scheithauer; James Carmichael; Armando Santoro; G. Ross; M. Marangolo

Lung Cancer | 2000

Comparison of Tirazone (Tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): Final results of the international Phase III CATAPULT II Trial

Frances A. Shepherd; G. Koschel; J. von Pawel; U Gatzmeier; N Van Zandwiyk; Penella J. Woll; R Van Klavren; P Krasko; P Desimone; Marianne Nicolson; W Pieters; R Bigelow; Augustin Rey; J Viallet; E Loh

Lung Cancer | 2000

Topotecan in second-line treatment of small cell lung cancer reduced toxicity with individualized therapy

R Koschel; R. M. Huber; U. Gatzemeier; H. Gosse; J. von Pawel; D. Hruska; J. Mezger; J. G. Saal

Lung Cancer | 2005

P-452 Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender

Chandra P. Belani; J. von Pawel; Anna Pluzanska; Vera Gorbounova; E. Kaukel; Karin Mattson; Rodryg Ramlau; P. Fidias; Michael Millward; Frank V. Fossella

Lung Cancer | 1997

41 Preliminary results of a randomized comparative phase III trial of topotecan (T) versus CAV as second-line therapy of small cell lung cancer (SCLC)

Joan H. Schiller; J. von Pawel; P. Clarke; J.P. Kleisbauer; T. Dobbs; N. Chrysson; Graham Dane; I. Hudson; M. DeWitte; S.Z. Fields

Lung Cancer | 2000

A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC)

Chandra P. Belani; J Rodriguez; J. von Pawel; Anna Pluzanska; Vera Gorbounova; Michael Millward; L. Bosquée; Y Kim; F Gamza; J Berille; L Hammershaimb; Frank V. Fossella

Lung Cancer | 2000

“Minimal N2-disease” (operable) stage IIIa non-small cell lung cancer: Prospectively randomized multicenter German phase-III-trial of surgery (S) followed by adjuvant radiotherapy (RTx) versus “Trimodality treatment” — Early results of feasibility and toxicity in this setting

Wilfried Eberhardt; Sönke Korfee; Horst Wagner; Georgios Stamatis; S. Bildat; Martin Stuschke; V Petersen; O Thetter; G Stüben; M.R Müller; Bernward Passlick; Christoph Pöttgen; L Hillejan; H Köhne; H Feldmann; B Botha; Hansjochen Wilke; S Gellert; H Sack; J. von Pawel; H Hirche; S. Seeber

Lung Cancer | 2006